Cemiplimab-rwlc

Placeholder slot

(seh-MIP-lih-mab)

Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.

US Brand Name(s)

Libtayo

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Cemiplimab-rwlc is approved to treat:

Basal cell carcinoma (BCC) (a type of skin cancer). It is used in patients whose cancer cannot be removed by surgery or has spread after treatment with hedgehog pathway inhibitor therapy or if hedgehog pathway inhibitor therapy cannot be used.
Cutaneous squamous cell carcinoma (a type of skin cancer) that has spread or cannot be treated with surgery or radiation therapy.
Non-small cell lung cancer. It is used in adults whose cancer has not spread outside the chest and cannot be treated with surgery or chemotherapy and radiation therapy or has spread to other parts of the body. It is used:
- Alone as the first treatment when the cancer has the PD-L1 protein but does not have a mutation in the EGFR, ALK, or ROS1 gene.
- With platinum chemotherapy as the first treatment when the cancer does not have a mutation in the EGFR, ALK, or ROS1 gene.

Cemiplimab-rwlc is also being studied in the treatment of other types of cancer.

More About Cemiplimab-rwlc

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Cemiplimab-rwlc - A lay language summary of important information about this drug that may include the following:

warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects

Targeted Cancer Therapies

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Cemiplimab-rwlc - Check for trials from NCI's list of cancer clinical trials now accepting patients.